ライフサイエンスコーパス: metabolic bone disease

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 om additional surveillance and management of metabolic bone disease.

2 been made in our understanding of pediatric metabolic bone disease.

3 investigating the treatment of patients with metabolic bone disease.

4 e a target for controlling mineralization in metabolic bone disease.

5 eta 2, may contribute to the pathogenesis of metabolic bone disease.

6 enues for enhancing bone repair and treating metabolic bone diseases.

7 nimal models with which to gain insight into metabolic bone diseases.

8 It is the second most common metabolic bone disease after osteoporosis, affecting 3%-

9 me a useful tool for assessing patients with metabolic bone disease and evaluating novel drugs being

10 , potentially making it possible to diagnose metabolic bone disease and track the impact of treatment

11 ased on knowledge gained in the treatment of metabolic bone diseases and in periodontal clinical tria

12 rveillance for inflammatory bowel disorders, metabolic bone disease, and malignancy is paramount when

13 y dialysis, improved nutrition, treatment of metabolic bone disease, and the use of recombinant human

14 on, and severe disease with renal stones and metabolic bone disease arises less frequently now than i

15 Wwox(-/-) mice develop metabolic bone disease, as a consequence of reduced seru

16 identified and comprehensively evaluated for metabolic bone disease at a median of 16 days (range 9-3

17 ldren with perpetrator-admitted child abuse, metabolic bone disease, birth trauma, or injury caused b

18 treatment of Paget disease of bone and other metabolic bone diseases but, to our knowledge, it has no

19 ic fibrosis-related diabetes, renal disease, metabolic bone disease, cancers, drug allergies and toxi

20 Osteoporosis is a metabolic bone disease characterized by low bone mass an

21 imal models that impact our understanding of metabolic bone disease have evolved dramatically.

22 e evaluation of the prevalence and extent of metabolic bone disease in RTS.

23 Deregulation of Cbfa1 results in metabolic bone diseases including osteoporosis and osteo

24 ytokines play a key role in various forms of metabolic bone diseases, including osteopenia and osteop

25 Metabolic bone disease is a common complication of chron

26 Preterm infants are at risk of metabolic bone disease (MBD) because of an inadequate mi

27 -related complications-including fatigue and metabolic bone disease-remain unavailable.

28 iphosphonate ((99m)Tc-MDP) in metastatic and metabolic bone disease require the measurement of free t

29 The model is also able to simulate metabolic bone diseases such as estrogen deficiency, vit

30 ly diagnosis and evaluation of therapies for metabolic bone diseases such as osteoporosis and some ca

31 entiation, and possibly for the treatment of metabolic bone diseases such as osteoporosis.

32 retarding the development or progression of metabolic bone disease; there is minimal risk, providing

33 thologic cascade leading to hyperthyroidism, metabolic bone disease, vascular calcification, and card

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。